One Click Group Limited

1CG

One Click Group Ltd. engages in the provision of financial services. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2017-04-28. The principal activities of the Company include online taxation preparation (and other life administration) software and services in Australia, offering a range of other financial services. Its wholly owned subsidiary is Mobile Business Devices Pty Ltd.

Aurora Energy Metals Limited

1AE

Aurora Energy Metals Ltd. engages in the exploration and development of mining properties. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2022-05-18. The AUP is located in Malheur County, Oregon, approximately 16 kilometers (km) northwest of the town of McDermitt, Nevada. The Company’s wholly owned subsidiary, Oregon Energy LLC, holds 100% of the Project as well as surrounding mining claims that extend to the west and to the south-east, across the Oregon/Nevada border. The mining claims are located on public lands in Oregon and Nevada and on a contiguous Company-owned block of private land in Nevada. The land tenure comprises approximately 451 unpatented lode mining claims and 71 unpatented placer mining claims in Malheur County, Oregon and 31 unpatented placer mining claims in Humboldt County, Nevada. The total area covered by these claims is approximately 43 square kilometers. The Project area is covered with a thin veneer of alluvium overlying lakebed sediments.

Algorae Pharmaceuticals Limited

1AI

Algorae Pharmaceuticals Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. The company is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.